Navigation Links
Political strife undermines HIV treatment
Date:3/12/2013

PROVIDENCE, R.I. [Brown University] As Kenyan citizens negotiated the tensions following the March 4 nationwide elections, memories of the violence that followed the December 2007 vote weighed heavily for many reasons. Among those in any nation with an HIV epidemic, argue authors of a new paper in AIDS Reviews, should be the long-term damage that political conflict can do to public health by disrupting treatment and thereby promoting resistance to antiretroviral drugs and treatment failure.

"It's the long-term consequences that make this a bigger issue," said lead author Marita Mann, who began studying the rise of drug resistant HIV in the wake of Kenya's 2007 strife when she was a Brown University Master of Public Health student. She is now a doctoral student at the University of Washington. "First there are the patients who are affected themselves during the conflict and may be resistant to treatment later on, but this also may lead to transmitted resistance that will be a bigger problem in the epidemic."

This time around in advance of the elections, Mann said, some Kenya health workers gave their patients extra supplies of medicine and papers that would help them transfer to another clinic in case they were displaced by new violence. In 2007, more than 1,000 Kenyans died and about 300,000 were displaced.

But many policymakers and health officials in HIV- and strife-ridden nations have not recognized the link between disrupted treatment and the potential for increased treatment failure and viral resistance, said senior author Dr. Rami Kantor, associate professor of medicine at Brown University and an infectious diseases physician at The Miriam Hospital in Providence.

The paper seeks to make that link clear by explaining how an unplanned treatment interruption can lead to increased viral drug resistance and treatment failure and by describing the research needed to mitigate the effects of treatment interruption in future conflicts.

The paper provides an overview, but the underlying concern is neither prospective nor hypothetical. In data they have presented at an international HIV conference but not yet published, Mann, Kantor, and colleagues from the AMPATH academic medical collaboration in Kenya found that after the 2007 violence, treatment in subjects whose drug regimens were interrupted by the conflict failed significantly more often than treatment in subjects who did not suffer a conflict-related disruption.

How conflict breeds resistance

HIV mutates often and research shows that as little as a single amino acid change can lead to drug resistance, the authors write. Modern "highly active" antiretroviral therapy (HAART) fights HIV with a potent mix of several drugs that attack the virus in multiple ways, successfully suppressing its replication in most patients.

When violence erupts, staying on those delicately balanced medications can become impossible. Drugs may no longer get to the clinic, patients and health care workers can become displaced, travel to the clinic can become unsafe, and patients can become profoundly depressed by the horror and tragedy around them.

After an unplanned treatment interruption takes place, the multipronged attack of HAART falls apart in an insidious fashion. Some drugs stay in the patient's system longer than others, leaving only a partial therapy in place. That partial therapy fails to stop the virus, instead encouraging the evolution of resistant strains. When full HAART resumes, the virus is better prepared to resist it.

Different variants of the virus will show differences in their likelihood of evolving resistance after an unplanned treatment interruption, the researchers predict.

What can be done

Mann said the steps her colleagues in Kenya took in advance of this year's elections providing extra medicine and clinic transfer papers were good ones to take at the level of an individual clinic, assuming they have extra doses of medicine on hand.

Similarly, Kantor said, "In the 2007 conflict AMPATH did a great job to do as much as possible to address the potential issues that we're raising and made great efforts to reach patients to resume care as soon they could, despite the post-conflict displacement and chaos. AMPATH has undertaken similar efforts and preparations for this month's Kenyan elections, including managing treatment stocks, on-call staff, logistical support, and participating in regional and national coordination."

But in the paper, the authors point out that neither health care providers nor officials have much of a rigorous knowledge base to refer to in managing unplanned treatment interruptions. And many officials do not consider or plan for the problem at all.

To better inform and prepare providers and officials, not only in Kenya but in other strife-prone nations with high rates of HIV infection, authors call for further research and attention to planning.

"Research is therefore needed to determine optimal ART stopping and restarting strategies for patients who find themselves in situations of unplanned interruptions," the authors write. "An additional strategy should encompass implementation of contingency treatment plans in developing countries addressing factors like consistent drug supplies, improved patient follow-up, education for healthcare providers, implementation of viral load monitoring and resistance testing and availability of multiple treatment regimens."

And if political leaders and their opponents happen to need one more reason to forgo violence, they can consider how it appears to worsen the HIV pandemic among their constituents.


'/>"/>

Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Related biology news :

1. Tendency to fear is strong political influence
2. Your body doesnt lie: People ignore political ads of candidates they oppose
3. New evidence that many genes of small effect influence economic decisions and political attitudes
4. Early antiretroviral treatment reduces viral reservoirs in HIV-infected teens
5. Sanford-Burnham and 60° Pharmaceuticals to pursue promising target for the treatment of dengue fever
6. New model could lead to improved treatment for early stage Alzheimers
7. U of M researchers identify genetic variation behind acute myeloid leukemia treatment success
8. Local therapy followed by treatment with EGFR TKI is well tolerated
9. Scientists identify molecular system that could help develop treatments for Alzheimers disease
10. UCSB study of cocaine addiction reveals targets for treatment
11. Research improving breast cancer treatment by targeting tumor initiating cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Political strife undermines HIV treatment
(Date:11/19/2016)... Nov. 18, 2016 Securus Technologies, a leading ... public safety, investigation, corrections and monitoring, announced today that ... ICSolutions, to have an independent technology judge determine who ... modern high tech/sophisticated telephone calling platform, and the best ... they do most of what we do – which ...
(Date:11/15/2016)... 15, 2016 Research and Markets has announced ... 2021" report to their offering. ... ... by 2021 from USD 6.21 Billion in 2016, growing at a ... of the bioinformatics market is driven by the growing demand for ...
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... , ... December 06, 2016 , ... ... December 1, 2016 asking the Federal Drug Administration (FDA) to consider OA as ... OA, OARSI is concerned about the growing population of OA patients, many of ...
(Date:12/6/2016)... NY (PRWEB) , ... December 06, 2016 , ... ... integrator of custom industrial automation and IT solutions, today announced the company has ... has reliably delivered professionally executed automation and control systems integration services to leading ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Theorem ... Chiltern International and focuses on clinical trial drug packaging, labeling, storage, reconciliation, ...
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016  Creative ... Santosh Kesari , MD, PhD, FANA, FAAN to the ... in neurology and clinical trials to assist the Company,s ... of stroke. The AmnioStem product is a universal donor stem ... therapeutic activity in animal models of stroke 1 .  ...
Breaking Biology Technology: